Astrocyte-Targeted Nanotherapeutics Modulate Iron Homeostasis in Cerebral Amyloid Angiopathy by Restoring the...

Area of Science:

• Neuroscience
• Materials Science
• Biomedical Engineering

Background:

• Cerebral amyloid angiopathy (CAA) is a prevalent neurological disorder characterized by iron dyshomeostasis.
• Aberrant ceruloplasmin localization and oxidative stress disrupt iron regulation in astrocytes, driving CAA progression.
• Current therapies lack specific targeting of astrocytic iron transport.

Purpose of the Study:

• To develop a targeted nanomedicine for restoring iron homeostasis in astrocytes.
• To investigate the therapeutic potential of DACe@ET in a mouse model of CAA.

Main Methods:

• Development of lattice-expanded Au/CeO2 nanoparticles loaded with ET-18-OCH3 and conjugated with DAG peptide (DACe@ET).
• Validation of antioxidant capacity using DFT calculations.
• Assessment of nanomedicine efficacy in 3 × Tg mouse model, evaluating iron deposition, amyloid-beta load, neurodegeneration, and cognitive function.

Main Results:

• DACe@ET successfully stabilized ceruloplasmin and normalized DMT1/FPN1 expression in astrocytes.
• The nanomedicine suppressed anomalous Fe2+ influx and promoted Fe2+ efflux and oxidation to Fe3+.
• In vivo studies showed reduced cerebral iron, decreased amyloid-beta burden, attenuated neurodegeneration, and improved cognition in treated mice.

Conclusions:

• Restoring astrocytic iron trafficking function is a viable therapeutic strategy for CAA.
• DACe@ET demonstrates potential as a disease-modifying therapy for CAA and other iron-related neurological disorders.
• This work establishes a foundation for translational research in neurological disorder therapies.